Brief Overview of Tesamorelin
A synthetic growth hormone releasing (GHRH) peptide, Tesamorelin consists of the same 44 amino acids present in GHRH that is produced by the human body. Originally developed to diminish visceral fat in HIV patients with a condition known as lipodystrophy, Tesamorelin was approved by the Food and Drug Administration (FDA) in 2010. It has demonstrated the ability to enhance quality of life in both physical and cognitive functions and is on the cutting edge of today’s male optimization science.
Tesamorelin works by increasing the IGF-1 levels and binding to GHRH receptors, enabling it to stimulate production with the pituitary gland at a rate that is approximately the same as the body’s naturally produced GHRH. Tesamorelin can also lower your level of triglycerides, which reduces the risk of heart disease. It has been shown to be extremely effective in reducing carotid intima media thickness (cIMT), which can help prevent atherosclerotic vascular disease. Tesamorelin also dramatically decreases visceral adipose tissue (VAT), and the amount C-reactive proteins (CRP). Excessive VAT can lead to a number of health problems, including coronary heart disease and diabetes. High levels of C-reactive proteins often indicate the presence of an inflammatory disorder.